$0.38
0.85% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
US52187K1016
Symbol
LPTX
Sector
Industry

Leap Therapeutics, Inc. Stock price

$0.38
-0.04 9.59% 1M
-2.52 86.97% 6M
-2.50 86.85% YTD
-1.98 83.98% 1Y
-10.72 96.59% 3Y
-25.22 98.52% 5Y
-78.22 99.52% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.00 0.85%
ISIN
US52187K1016
Symbol
LPTX
Sector
Industry

Key metrics

Market capitalization $15.66m
Enterprise Value $-17.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.29
P/B ratio (TTM) P/B ratio 0.75
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-71.15m
Free Cash Flow (TTM) Free Cash Flow $-59.26m
Cash position $32.71m
EPS (TTM) EPS $-1.68
Short interest 6.25%
Show more

Is Leap Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Leap Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Leap Therapeutics, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Leap Therapeutics, Inc.:

Hold
100%

Financial data from Leap Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
9% 9%
-
- Research and Development Expense 59 59
29% 29%
-
-71 -71
20% 20%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -71 -71
20% 20%
-
Net Profit -69 -69
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Leap Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Leap Therapeutics, Inc. Stock News

Neutral
PRNewsWire
19 days ago
CAMBRIDGE, Mass. , May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025.
Neutral
PRNewsWire
about one month ago
FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will presen...
Neutral
PRNewsWire
about 2 months ago
Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET CAMBRIDGE, Mass.
More Leap Therapeutics, Inc. News

Company Profile

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Head office United States
CEO Doug Onsi
Employees 52
Founded 2011
Website www.leaptx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today